Enliven Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Enliven Therapeutics

10/08/2023 22:59

* Enliven Therapeutics Inc  ELVN.OQ  reported a quarterly
adjusted
loss of 41 cents​​ per share for the quarter ended in June. The
mean expectation of three analysts for the quarter was for a
loss of 36 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Enliven Therapeutics Inc's reported EPS for the quarter
was a
loss of 41 cents​.
    * The mean earnings estimate of analysts had risen by
about 9.3%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Enliven Therapeutics Inc shares had fallen by 12.3% this
quarter and gained 9.4% so far this year.
    * The company reported a quarterly loss of $16.72 million.
    * Wall Street's median 12-month price target for Enliven
Therapeutics Inc is $32.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 10 at 09:59 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.36          -0.41          Missed
 Mar. 31 2023      -0.63          -0.80          Missed
 Sep. 30 2022      -1.00          -0.72          Beat